Kevin J Frankowski

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5828797/publications.pdf

Version: 2024-02-01

35	803	623734	501196
papers	citations	14 h-index	28 g-index

37	37	37	1229
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Development of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors. Journal of Biological Chemistry, 2013, 288, 36703-36716.	3.4	123
2	Syntheses of the Stemona Alkaloids (Â±)-Stenine, (Â±)-Neostenine, and (Â±)-13-Epineostenine Using a Stereodivergent Dielsâ€“Alder/Azido-Schmidt Reaction. Journal of the American Chemical Society, 2008, 130, 6018-6024.	13.7	103
3	Practical Electrochemical Anodic Oxidation of Polycyclic Lactams for Late Stage Functionalization. Angewandte Chemie - International Edition, 2015, 54, 10555-10558.	13.8	74
4	Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Science Translational Medicine, 2018, 10, .	12.4	55
5	Structureâ€“Activity Relationship Studies of Functionally Selective Kappa Opioid Receptor Agonists that Modulate ERK 1/2 Phosphorylation While Preserving G Protein Over Î²Arrestin2 Signaling Bias. ACS Chemical Neuroscience, 2015, 6, 1411-1419.	3.5	48
6	Benzothiazole and Pyrrolone Flavivirus Inhibitors Targeting the Viral Helicase. ACS Infectious Diseases, 2015, 1, 140-148.	3.8	44
7	Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. ACS Chemical Neuroscience, 2012, 3, 221-236.	3.5	42
8	Investigation of the role of Î²arrestin2 in kappa opioid receptor modulation in a mouse model of pruritus. Neuropharmacology, 2015, 99, 600-609.	4.1	38
9	Identification of Positive Allosteric Modulators of the D₁ Dopamine Receptor That Act at Diverse Binding Sites. Molecular Pharmacology, 2018, 94, 1197-1209.	2.3	35
10	Synthesis and receptor profiling ofStemonaalkaloid analogues reveal a potent class of sigma ligands. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6727-6732.	7.1	30
11	Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPÎ³S binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting. Neuropharmacology, 2015, 99, 131-141.	4.1	24
12	N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: Selective and Nonbasic Îº-Opioid Receptor Ligands. ACS Medicinal Chemistry Letters, 2010, 1, 189-193.	2.8	22
13	Explorations of Stemona Alkaloid-Inspired Analogues: Skeletal Modification and Functional Group Diversification. ACS Combinatorial Science, 2008, 10, 721-725.	3.3	20
14	Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D₃ Dopamine Receptor Agonist. Journal of Medicinal Chemistry, 2020, 63, 5526-5567.	6.4	15
15	Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the D2 Dopamine Receptor. Frontiers in Synaptic Neuroscience, 2018, 10, 2.	2.5	14
16	Evaluating p97 Inhibitor Analogues for Potency against p97â€“p37 and p97â€“Npl4â€“Ufd1 Complexes. ChemMedChem, 2016, 11, 953-957.	3.2	13
17	Autophagy activation by novel inducers prevents BECN2-mediated drug tolerance to cannabinoids. Autophagy, 2016, 12, 1460-1471.	9.1	12
18	Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. Journal of Medicinal Chemistry, 2017, 60, 6364-6383.	6.4	12

#	Article	IF	Citations
19	Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy. ACS Chemical Biology, 2015, 10, 1887-1896.	3.4	10
20	Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion. Nature Microbiology, 2020, 5, 1532-1541.	13.3	10
21	Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 1067-1080.	2.3	9
22	Potency enhancement of the Î¹-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif. Bioorganic and Medicinal Chemistry, 2015, 23, 3948-3956.	3.0	7
23	Development of pyrimidone D1 dopamine receptor positive allosteric modulators. Bioorganic and Medicinal Chemistry Letters, 2021, 31, 127696.	2.2	6
24	Decahydrobenzoquinolin-5-one sigma receptor ligands: Divergent development of both sigma 1 and sigma 2 receptor selective examples. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5689-5694.	2.2	5
25	Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis. Journal of Medicinal Chemistry, 2022, 65, 8303-8331.	6.4	4
26	Divergent Electrochemical Carboamidation of Cyclic Amines. Journal of Organic Chemistry, 2022, 87, 1173-1193.	3.2	3
27	Small-Molecule Disruptors of Mutant Huntingtinâ€“Calmodulin Proteinâ€“Protein Interaction Attenuate Deleterious Effects of Mutant Huntingtin. ACS Chemical Neuroscience, 0, , .	3.5	3
28	Discovery of sultam-containing small-molecule disruptors of the huntingtinâ€“calmodulin proteinâ€“protein interaction. Medicinal Chemistry Research, 2020, 29, 1187-1198.	2.4	2
29	Development of biased agonists at the kappa opioid receptor.. FASEB Journal, 2013, 27, .	0.5	2
30	Advances in Sulfonamide Kappa Opioid Receptor Antagonists: Structural Refinement and Evaluation of CNS Clearance. ACS Chemical Neuroscience, 2022, 13, 1315-1332.	3.5	1
31	Structureâ€“activity relationship investigation of triazole-based kappa opioid receptor agonists. Medicinal Chemistry Research, 2021, 30, 1386-1396.	2.4	0
32	Development of functionally selective agonists at the kappa opioid receptor (KOR). FASEB Journal, 2013, 27, lb551.	0.5	0
33	Mutant Huntingtinâ€Calmodulin Interaction: Potential Therapeutic Target for Huntington's Disease. FASEB Journal, 2019, 33, 501.16.	0.5	0
34	Identification of a Novel Negative Allosteric Modulator of the D3 Dopamine Receptor. FASEB Journal, 2019, 33, 503.3.	0.5	0
35	Structureâ€“Activity Relationships of a Negative Allosteric Modulator of the D3 Dopamine Receptor and Investigation of its Binding Site. FASEB Journal, 2022, 36, .	0.5	0